Qu Biologics Enrolls First Patient in Phase 1/2 Clinical Trial of QBECO SSI for the Treatment of Crohn's Disease
June 11, 2013 16:22 ET | Qu Biologics
VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 11, 2013) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to "reboot" the...
Qu Biologics Welcomes Dr. Richard Fedorak and Dr. William Sandborn to Newly Formed IBD Advisory Team for Crohn's Disease Clinical Trial
May 30, 2013 13:43 ET | Qu Biologics
VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 30, 2013) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to "reboot" the body's...
Early Diagnosis and Public Awareness of Crohn's and Ulcerative Colitis Critical to Patient Care
November 23, 2011 09:00 ET | Crohn's & Colitis Foundation of Canada (CCFC)
TORONTO, ONTARIO--(Marketwire - Nov. 23, 2011) - Imagine experiencing agonizing and debilitating pain that lasts for hours, months and even a year without a Doctor or Medical Practitioner...
Research Indicates Synthetic Compound NV-52 May Be Useful in Treatment of Inflammatory Bowel Disease
November 13, 2007 08:04 ET | Novogen, Limited
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - November 13, 2007) - An article published in a recent edition of the peer review journal Expert Opinion, Vol. 16, No. 8, reveals the compound...